Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
$2.22
+0.9%
$2.85
$1.14
$7.20
$132.97M0.92787,328 shs410,852 shs
(ANTX) stock logo
ANTX
(ANTX)
$1.18
-3.7%
$0.00
$0.87
$3.07
$33.76M0.15351,065 shs83,337 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$9.72
-2.6%
$9.70
$8.06
$18.75
$129.94M1.7446,385 shs39,235 shs
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$12.42
-3.1%
$15.60
$11.13
$98.00
$120.39M2.6699,486 shs91,326 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
+0.91%-1.33%-19.57%-64.98%-41.42%
(ANTX) stock logo
ANTX
(ANTX)
+0.86%+0.43%-6.00%+5.38%-44.58%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-2.61%-0.10%-3.19%-15.77%-26.31%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-3.12%-16.08%-28.91%-49.54%-74.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
2.1746 of 5 stars
3.52.00.00.02.61.70.6
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.4415 of 5 stars
3.50.00.00.01.43.30.0
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1.9907 of 5 stars
4.60.00.00.02.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
3.00
Buy$9.50327.93% Upside
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5027.66% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00301.23% Upside
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.29
Buy$102.43724.71% Upside

Current Analyst Ratings Breakdown

Latest ANTX, ALDX, GLSI, and KRRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.00
5/8/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$115.00 ➝ $100.00
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/29/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/16/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/7/2025
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $9.00
4/4/2025
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$2.04 per shareN/A
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$4.82M24.19N/AN/A$21.19 per share0.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$37.54M-$0.97N/AN/AN/AN/A-43.01%-33.62%8/7/2025 (Estimated)
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%8/12/2025 (Estimated)

Latest ANTX, ALDX, GLSI, and KRRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/14/2025Q1 2025
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$0.25-$0.17+$0.08-$0.17($0.80) millionN/A
5/7/2025Q1 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/18/2025Q4 2024
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.33-$2.26+$0.07-$2.26N/A$2.27 million
3/6/2025Q4 2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
$0.03-$0.27-$0.30-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
0.18
6.80
6.80
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
6.91
6.91
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
11.23
11.23

Institutional Ownership

CompanyInstitutional Ownership
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
59.71%
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%

Insider Ownership

CompanyInsider Ownership
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
9.60%
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
1559.90 million54.49 millionOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.35 millionNot Optionable
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.86 millionNo Data

Recent News About These Companies

FY2025 EPS Forecast for Korro Bio Decreased by Analyst
Korro Bio to Cut 20% of Workforce
Korro Bio to Cut 20% of Workforce

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aldeyra Therapeutics stock logo

Aldeyra Therapeutics NASDAQ:ALDX

$2.22 +0.02 (+0.91%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.22 -0.01 (-0.23%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$9.72 -0.26 (-2.61%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$9.34 -0.38 (-3.90%)
As of 05/28/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$12.42 -0.40 (-3.12%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$12.57 +0.15 (+1.21%)
As of 05/28/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.